ENDO RECEIVES FDA APPROVAL FOR OPANA ER (OXYMORPHONE HCL) EXTENDED-RELEASE

Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the company's New Drug Applications (NDAs) for its extended- release and immediate-release formulations of oxymorphone hydrochloride. These products are now known under the trade names Opana ER tablets and Opana tablets.

Pipeline Review (http://www.pipelinereview.com/joomla/content/view/4712/109/)